Living with hyperparathyroidism can be physically draining and emotionally frustrating. The condition often causes vague yet persistent symptoms like deep fatigue, “brain fog,” body aches, and mood changes, which can easily be mistaken for stress or aging. Beyond these daily discomforts, the condition disrupts the body’s essential calcium balance, potentially leading to weakened bones or the formation of painful kidney stones. Treatment is essential not only to improve how you feel day-to-day but also to protect your kidneys and skeletal system from long-term damage. 

Treatment plans are highly individualized because hyperparathyroidism can stem from a tumor on the parathyroid glands (primary) or result from another condition like chronic kidney disease (secondary). Medication choices depend on the severity of calcium levels, the underlying cause, and individual health factors. 

Overview of treatment options for Hyperparathyroidism 

The main goal of hyperparathyroidism treatment is to restore calcium and parathyroid hormone (PTH) levels to a normal, healthy range. Achieving this balance resolves symptoms, stops the ongoing loss of bone density, and prevents complications like kidney stones. 

For primary hyperparathyroidism where the glands themselves are the problem, surgery (parathyroidectomy) to remove the overactive gland is often the standard and most effective path to a cure. Medications, however, play a critical role for patients who are not suitable candidates for surgery, those with very mild disease that is being monitored, or individuals with secondary hyperparathyroidism caused by conditions like kidney failure. Lifestyle adjustments, such as maintaining proper hydration and ensuring adequate Vitamin D intake, support overall health but cannot replace medication or surgery. 

Medications used for Hyperparathyroidism 

When a non-surgical approach is chosen, medications are prescribed to control the overproduction of PTH and shield the skeletal system. 

Calcimimetics: This class of drugs, including the medication cinacalcet, is used to treat secondary hyperparathyroidism in patients on dialysis and can be used for primary cases when surgery is unsuitable. These medications help lower PTH and blood calcium levels. Patients should expect to see lab values begin to change within a few weeks of starting treatment, though the final dosage may require monitoring and adjustment over a couple of months. 

Bisphosphonates: Drugs such as alendronate are used to directly address bone complications. They are not designed to treat the parathyroid glands themselves. Instead, they protect bones from the destructive effects of chronic high PTH, which can cause significant bone density loss (osteoporosis). They are often prescribed to patients with hyperparathyroidism who have documented bone thinning. 

Hormone Replacement Therapy: For certain postmenopausal women, hormone therapy may be considered as an option to help the bones better retain calcium, providing additional protection against bone loss. 

How these medications work 

The major drug classes for hyperparathyroidism regulate hormones and protect the skeleton using distinct mechanisms. 

Calcimimetics act as a clever “signal tricker” for the parathyroid glands. The parathyroid glands contain sensors that monitor calcium in the bloodstream. In hyperparathyroidism, these sensors become less sensitive, forcing the glands to overproduce PTH. Calcimimetics bind to these sensors, essentially mimicking a high level of calcium. This tricks the glands into decreasing the production and secretion of PTH, which, in turn, helps lower the concentration of calcium in the blood. 

Bisphosphonates act to prevent bone resorption. High levels of PTH normally stimulate bone-resorbing cells (osteoclasts). Bisphosphonates adhere directly to bone tissue and inhibit the activity of these osteoclasts. By slowing down the rate at which bone is broken down, bisphosphonates help the body preserve skeletal density, protecting against fractures and bone pain. 

Side effects and safety considerations 

Thyroid-related medications require vigilant monitoring, and any side effects are typically managed through dose adjustment. 

Calcimimetics commonly cause nausea and vomiting, and risk hypocalcemia, which may present as numbness, tingling, or muscle cramps. Bisphosphonates can cause stomach upset or esophageal irritation, requiring them to be taken with water while remaining upright. Regular blood tests for calcium, phosphorus, and PTH are necessary for safe and effective dosing (NIH, 2023). Patients with a history of seizures or certain cardiac issues need special monitoring with calcimimetics. Seek immediate care for severe low calcium symptoms like muscle spasms (tetany) or an allergic reaction. 

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care. 

References 

  1. National Institutes of Health. https://www.nih.gov 
  1. Mayo Clinic. https://www.mayoclinic.org 
  1. MedlinePlus. https://medlineplus.gov 
  1. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov 

Medications for Hyperparathyroidism

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Hyperparathyroidism.

Found 7 Approved Drugs for Hyperparathyroidism

Calcitriol

Brand Names
Calcitrol, Rocaltrol, Vectical

Calcitriol

Brand Names
Calcitrol, Rocaltrol, Vectical
Predialysis Patients Calcitriol capsules re indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of.

Sensipar

Generic Name
Cinacalcet

Sensipar

Generic Name
Cinacalcet
Sensipar is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis.

Zemplar

Generic Name
Paricalcitol

Zemplar

Generic Name
Paricalcitol
Paricalcitol Injection is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. Paricalcitol Injection is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease on dialysis.

Rayaldee

Generic Name
Calcifediol

Rayaldee

Generic Name
Calcifediol
RAYALDEE is a vitamin D 3 analog indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Limitations of Use RAYALDEE is not indicated for the treatment of secondary hyperparathyroidism in patients with stage 5 chronic kidney disease or in patients with end-stage renal disease on dialysis. RAYALDEE is a vitamin D 3 analog indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. ( 1 ) Limitations of Use: RAYALDEE is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis. ( 1 )

Pamidronate

Generic Name
Pamidronate

Pamidronate

Generic Name
Pamidronate
Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥ 3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥ 50% in at least 50% of patients, and by ≥ 30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated.
Showing 1-5 of 7
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances